Protocolos clínicos

Directrices procedimentales completas desde la evaluación previa hasta el seguimiento

Última actualización: May 27, 2026Revisado por: Andrei Dokukin, MDNivel 2 — evidencia clínica (uso off-label)

FDA-aligned clinical protocolsOff-label expansion guidance

Evidencia clínica — No evaluada por la FDA

Estos protocolos sintetizan guías clínicas publicadas, revisiones sistemáticas y mejores prácticas institucionales. Los profesionales deben adaptarlos a su entorno clínico específico y cumplir con las leyes de alcance de práctica estatales aplicables. Toda hirudoterapia debe ser realizada por o bajo la supervisión de profesionales de la salud licenciados.

Capítulo 22: Protocolos clínicos — Referencia completa

Esta página presenta el marco completo de protocolos clínicos para la terapia con sanguijuelas medicinales, cubriendo configuración de instalaciones, evaluación preprocedimiento, técnica de aplicación, monitoreo, cuidado postprocedimiento, manejo de complicaciones y documentación. Cada umbral, dosis y algoritmo proviene de evidencia revisada por pares y consenso experto (Mumcuoglu 2014; Whitaker 2012; Herlin 2017; Michalsen 2003, 2008, 2018).

La terapia con sanguijuelas medicinales (Hirudo verbana) es un procedimiento autorizado por FDA 510(k) que utiliza un dispositivo médico autorizado por 510(k) (categoría pre-enmienda no clasificada). Los resultados clínicos exitosos dependen de la adherencia rigurosa a protocolos estandarizados en cada fase: preparación de instalaciones, evaluación del paciente, selección y aplicación de sanguijuelas, monitoreo intraoperatorio, cuidado postprocedimiento de heridas, profilaxis antibiótica y manejo de complicaciones. Esta página proporciona la referencia procedimental completa.

Principios clave

Paradoja de esterilidad: El procedimiento utiliza un organismo vivo con un simbionte intestinal obligado (Aeromonas hydrophila). La prevención de infecciones depende de la profilaxis antibiótica, no solo de la técnica estéril.
La pérdida de sangre es acumulativa: Cada sanguijuela extrae 15–65 mL. Los protocolos microquirúrgicos seriados (3–6 sanguijuelas c/4h × 5 días) pueden producir 2–5 litros de pérdida sanguínea acumulada. El 49.75% de los pacientes microquirúrgicos requieren transfusión (Whitaker 2012).
El consentimiento es crítico: El consentimiento informado es el área de mayor riesgo medicolegal. Los pacientes deben comprender la cicatriz en forma de Y, el sangrado de 4 a 24 horas, el riesgo de infección del 7–20% sin profilaxis y la posibilidad de transfusión.
Nunca jalar a la fuerza: La remoción forzada arriesga la regurgitación de Aeromonas en la herida, avulsión de dientes y trauma tisular.
Documentar todo: Lista de verificación preprocedimiento, notas SOAP, órdenes postprocedimiento e instrucciones de alta forman un registro medicolegal defendible.

Requisitos de instalaciones y equipamiento

Especificaciones de la sala de procedimientos

Parámetro	Especificación	Justificación
Temperature	22–25°C (72–77°F)	Leeches become sluggish below 20°C; above 25°C increases metabolic stress
Lighting	Bright, adjustable overhead	Precise site visualization; dimming for patient comfort during wait
Ventilation	Adequate airflow; no fragrances	Leeches refuse attachment in presence of perfumes, disinfectant fumes, or strong odors
Surfaces	Nonporous, easily disinfected	Blood and body fluid cleanup; OSHA compliance
Sink access	Handwashing station within room	Hand hygiene before/after; water for leech handling
Patient positioning	Adjustable chair or examination table	Patient must remain comfortable for 30–90 minutes; recline capability for vasovagal

Lista de equipamiento (19 artículos)

#	Artículo	Especificación	Costo est. (USD)
1	FDA-cleared medicinal leeches	Hirudo verbana; suppliers: Ricarimpex (France), Biopharm (UK), Carolina Biological (US)	$10–15/leech
2	Storage containers	Glass jars, 1–3L, wide-mouth	$5–15
3	Dechlorinated water	Bottled spring water or tap water aged 24h uncovered	$3–10
4	Aquarium thermometer	Submersible, range 10–30°C	$3–8
5	Nitrile examination gloves	Box of 100, nonlatex (latex may deter leeches)	$8–15
6	Blunt-tipped forceps	Stainless steel, for leech transfer (not grasping)	$5–10
7	Syringe guides	5–10 mL syringes with plunger removed; directs leech to precise site	$0.50 each
8	Sterile gauze pads	4×4 inch, non-woven; large quantity for post-detachment bleeding	$5–10/pack
9	Semi-permeable membrane	Thin barrier film to confine leeches to application zone	$5–15
10	Absorbent underpads	Disposable, waterproof backing, for bed/chair protection	$10–20/pack
11	Biohazard waste container	Red, leak-proof, biohazard labeled	$15–30
12	70% ethyl alcohol	500 mL; for euthanizing used leeches and detachment stimulation	$5–10
13	Medical tape	Hypoallergenic, paper or silk; for dressing securement	$3–5
14	Application window/ring	Adhesive barrier to restrict leech migration; optional	$5–10
15	Vital signs monitor	Blood pressure cuff, pulse oximeter, thermometer	$50–300
16	Timer	Digital timer for feeding duration and monitoring intervals	$5–10
17	Camera / phone	Clinical photography for wound documentation (with consent)	Existing
18	Sterile needle (25G)	For producing blood droplet to encourage attachment	$0.10 each
19	Emergency supplies kit	See Emergency Supplies section below	$200–500
Costo total de inicio (excluyendo sanguijuelas)		$350-$1,000

Almacenamiento y aseguramiento de calidad de sanguijuelas

Protocolo de almacenamiento (8 puntos)

Use glass jars (1–3L) with wide mouths — never plastic (chemical leaching)
Fill with dechlorinated water: bottled spring water OR tap water left uncovered 24 hours to off-gas chlorine
Change water every 3–4 days; inspect for turbidity, dead leeches, or mucus
Maximum density: 10 leeches per liter of water
Cover with 4-layer gauze secured by rubber band — leeches are strong escape artists
Store at 18–22°C (64–72°F); away from sunlight and vibration
No aromatic substances in storage area (perfumes, cleaning agents, hand sanitizer)
Never mix fed and unfed leeches — fed leeches release digestive enzymes; unfed leeches may cannibalize

Shelf life: Use within 30 days of receipt for optimal feeding activity and therapeutic efficacy.

Daily inspection: Check for lethargic or dead leeches (pale, non-responsive to touch); remove immediately.

Indicadores de calidad para sanguijuelas listas para terapia (5 criterios)

Active swimming: Vigorous, sinusoidal movement when container is gently agitated
Firm body: Muscular tone when lifted with blunt forceps; not flaccid or bloated
Dark coloration: Healthy olive-green to dark brown dorsal surface; ventral lighter
Responsive to stimulation: Contracts rapidly when touched; anterior sucker actively explores
No visible lesions: No white patches, ulcers, swelling, or mucus coating

Criterios de rechazo

Descartar sanguijuelas que estén letárgicas, pálidas, hinchadas, tengan manchas blancas o no se contraigan cuando se estimulan. No usar sanguijuelas almacenadas por >30 días. Una sanguijuela que se niega a adherirse a piel preparada y tibia con una gota de sangre debe ser reemplazada — no insistir con una sanguijuela renuente.

Suministros de emergencia

Todos los suministros de emergencia deben estar inmediatamente accesibles en la sala de procedimientos antes de iniciar la terapia con sanguijuelas. Verificar fechas de vencimiento mensualmente.

#	Artículo	Especificación	Propósito
1	Epinephrine autoinjector	0.3 mg IM (adult); 0.15 mg (pediatric)	Anaphylaxis first-line treatment
2	Diphenhydramine	50 mg IM injectable	Allergic reaction; adjunct to epinephrine
3	Silver nitrate sticks	75% silver nitrate / 25% potassium nitrate	Chemical cauterization of bleeding bite wounds
4	Topical thrombin / Gelfoam	Absorbable gelatin sponge or topical bovine thrombin	Hemostasis for refractory oozing
5	Suture kit	3-0 and 4-0 absorbable suture with needle driver	Figure-of-eight closure for refractory bleeding
6	Normal saline	500 mL bags (0.9% NaCl), ×2	Volume resuscitation, wound irrigation
7	Aminocaproic acid	Oral or IV formulation	Antifibrinolytic for refractory bleeding
8	Blood pressure cuff	Manual or automatic, multiple cuff sizes	Hemodynamic monitoring
9	Pulse oximeter	Fingertip, with alarm capability	Continuous oxygenation monitoring
10	IV access supplies	18G and 20G catheters, tubing, tape, tourniquet	Rapid vascular access for resuscitation
11	Oxygen delivery	Nasal cannula + non-rebreather mask; portable O2 tank	Respiratory support for anaphylaxis/vasovagal
12	Albuterol inhaler	MDI with spacer	Bronchospasm management in allergic reaction

Costo estimado: $200–500 para kit completo de emergencia. Verificar fechas de vencimiento durante la revisión mensual de equipamiento.

Evaluación preprocedimiento

Detección de historia del paciente

Una historia dirigida enfocada en riesgo de sangrado, vulnerabilidad a infecciones y exposición previa a sanguijuelas es esencial antes de iniciar la terapia. Las siguientes 7 condiciones requieren evaluación específica:

Condición	Enfoque de detección	Acción
Bleeding disorders	Hemophilia, von Willebrand, thrombocytopenia, liver-related coagulopathy	Hematology consult; may be absolute CI if severe
Hepatic disease	Cirrhosis, synthetic dysfunction, portal hypertension	Check PT/INR, albumin; coagulopathy risk
Renal disease	CKD stage, dialysis, uremic platelet dysfunction	Check BMP, bleeding time; dose-adjust antibiotics
Immunocompromised	HIV/AIDS, transplant, chemotherapy, biologics, chronic steroids	Do NOT hold immunosuppressants; increase infection surveillance
Cardiovascular disease	Anticoagulation status, prosthetic valves, recent MI/stent	Coordinate med hold with cardiology; bridge if needed
Diabetes mellitus	Type, HbA1c, neuropathy, peripheral vascular disease	Increased infection risk; impaired wound healing; closer follow-up
Prior leech therapy	Previous reactions, allergy, infection, sensitization	IgE sensitization possible; if prior anaphylaxis = absolute CI

Detección específica de alergias

Alergias a antibióticos

Pregunte específicamente sobre alergias a fluoroquinolonas (cipro) y sulfonamidas (TMP-SMX) — estos son los dos agentes profilácticos de primera línea. Documente el tipo de reacción (erupción vs. anafilaxia) para guiar la selección alternativa.

Alergia a la SGS de sanguijuela

El prurito ocurre en el 37–75% de los pacientes (no es alergia). Las reacciones verdaderas mediadas por IgE a la hirudina y otras proteínas salivales son raras pero documentadas. La anafilaxia previa a la terapia con sanguijuelas es una contraindicación absoluta.

Alergia al látex

Use guantes de nitrilo exclusivamente. Los guantes de látex cerca del sitio de aplicación pueden transferir residuos que disuaden la adhesión de la sanguijuela y desencadenar reacción del paciente.

Historia de la enfermedad actual (HPI): Documente la indicación específica para la terapia con sanguijuelas, historial quirúrgico relevante (reimplantación, tipo de colgajo, cronología) y estado actual del tejido/articulación siendo tratado.

Consideraciones para pacientes ancianos (>65 años)

Los pacientes ancianos requieren evaluación preprocedimiento y monitoreo adicionales debido a cambios fisiológicos relacionados con la edad que afectan la seguridad y resultados del tratamiento.

Evaluación preprocedimiento

Comprehensive medication review: Document all anticoagulants, antiplatelets, NSAIDs, and supplements (fish oil, vitamin E, ginkgo). Polypharmacy is common in elderly patients and significantly increases bleeding risk.
Renal function assessment: Calculate CrCl (Cockcroft-Gault) for antibiotic dosing. Fluoroquinolone prophylaxis requires dose adjustment if CrCl <50 mL/min. Ciprofloxacin: 250 mg BID if CrCl 30–50; avoid if <30.
Baseline hematology: CBC with differential, INR/aPTT, BMP. Lower transfusion threshold (Hgb <8 g/dL in patients with cardiovascular disease). Type and screen for patients on serial protocols.
Skin integrity assessment: Age-related skin thinning increases wound healing time and scarring risk. Document skin condition at application site. Consider reduced leech numbers per session.
Cardiovascular assessment: Evaluate for orthostatic hypotension risk, especially with anticipated blood loss. Heart failure patients may have reduced blood volume tolerance.

Ajustes de monitoreo

More frequent vital signs: Q2h (vs standard Q4h) during active treatment, especially in patients with cardiovascular comorbidities.
Lower intervention thresholds: Consider transfusion at Hgb <8 g/dL (vs <7 in younger patients), particularly in patients with coronary artery disease.
Extended post-procedure observation: Minimum 2 hours post-detachment (vs 1 hour standard) due to delayed recognition of symptoms in elderly patients.
Fall prevention: Assess mobility and balance before discharge. Ensure caregiver availability for first 24 hours post-treatment.
Wound care education: Provide written instructions with large font. Confirm understanding with teach-back method. Engage caregiver in discharge education.

Requisitos de laboratorio

Prueba	Propósito	Umbral de acción	Acción
CBC (Complete Blood Count)	Baseline hemoglobin/hematocrit and platelet count	Hgb <8 g/dL; Plt <50,000/µL	Hgb <8: transfuse before proceeding. Plt <50K: relative CI — hematology consult, weigh risk/benefit
PT / INR	Coagulation status (warfarin, liver disease)	INR >3.0; INR 2.0–3.0	INR >3.0: hold warfarin, recheck, do not proceed. INR 2.0–3.0: proceed with caution, extra hemostasis supplies
aPTT	Intrinsic pathway / heparin monitoring	>2× upper limit of normal	Investigate cause; consider heparin hold or reversal; consult hematology
Type & Screen	Blood bank readiness for transfusion	Required for all surgical/inpatient	49.75% of microsurgical patients require transfusion (Whitaker 2012). Must be current (<72h)
BMP (Basic Metabolic Panel)	Renal function baseline; electrolyte status	Cr >2.0 or GFR <30	Dose-adjust renally cleared antibiotics; closer monitoring of fluid balance in multi-day protocols
Blood Cultures	Rule out active sepsis if febrile	T >38.0°C or clinical suspicion	Active sepsis = absolute contraindication to leech therapy. Treat infection first.

Excepción ambulatoria

Para aplicaciones musculoesqueléticas ambulatorias de sesión única (2–8 sanguijuelas): hemograma + TP/INR son suficientes en pacientes sanos sin historial de sangrado ni uso de anticoagulantes. Tipo y prueba cruzada, TTPa, BMP y hemocultivos no se requieren rutinariamente para sesiones ambulatorias de bajo volumen.

Manejo de medicación

Los anticoagulantes, agentes antiplaquetarios y AINE aumentan significativamente el riesgo de sangrado. Los siguientes cronogramas de suspensión equilibran el riesgo de sangrado contra el riesgo tromboembólico. Nota: El 54.29% de los protocolos microquirúrgicos usan anticoagulación concomitante (Whitaker 2012) — las suspensiones de medicación pueden no aplicar en contextos de salvamento quirúrgico.

Clase de fármaco	Ejemplos	Tiempo de suspensión	Notas
Warfarin	Coumadin	Hold 3–5 days	Target INR <2.0 for elective; bridge with LMWH if high thrombotic risk (mechanical valve, recent DVT)
DOACs	Rivaroxaban, apixaban, dabigatran, edoxaban	Hold 24–48h	Shorter half-life than warfarin; 48h for dabigatran if CrCl <50; reversal agents available (idarucizumab, andexanet)
Heparin (IV UFH)	Unfractionated heparin drip	Hold 4–6h	Check aPTT before proceeding; protamine available for reversal
LMWH	Enoxaparin, dalteparin	Hold 12–24h	12h for prophylactic dose; 24h for therapeutic dose; partial protamine reversal
Aspirin	ASA 81–325 mg	Do NOT routinely hold (surgical); Hold 7 days (elective)	Irreversible COX-1 inhibition; in microsurgical salvage, aspirin is often deliberately continued for antiplatelet effect
Clopidogrel	Plavix	Hold 5–7 days	Irreversible P2Y12 inhibition; coordinate with cardiology if recent stent (<12 months)
NSAIDs	Ibuprofen, naproxen, diclofenac, ketorolac	Hold 3–5 days pre-procedure	Reversible COX inhibition; also avoid post-procedure for 48h (prolongs bleeding from hirudin's anticoagulant effect)
Immunosuppressants	Tacrolimus, mycophenolate, methotrexate, biologics	Do NOT hold	Holding risks rejection/flare. Instead: increase infection surveillance, lower threshold for empiric antibiotics, closer wound monitoring

Consentimiento informado

El consentimiento informado es el área de mayor riesgo de mala praxis en la terapia con sanguijuelas. La documentación debe ser detallada, firmada e incluir todos los elementos a continuación. El consentimiento solo verbal es insuficiente.

Elementos requeridos del consentimiento

Naturaleza del procedimiento

Live FDA 510(k)-cleared medical devices (Hirudo verbana)
Leeches attach via tripartite jaw producing a characteristic Y-shaped bite mark
Feeding duration: 20–45 minutes per leech (up to 60–90 min for large leeches)
Leeches inject saliva containing hirudin (anticoagulant) and other bioactive compounds
Post-detachment oozing is expected and therapeutic (continued decompression)

Beneficios esperados

Venous decongestion and improved tissue perfusion
Tissue/flap salvage (78% overall salvage rate; Whitaker 2012)
Pain reduction in musculoskeletal conditions
Local anti-inflammatory and analgesic effects via salivary compounds

Alternativas a la terapia con sanguijuelas

Heparin-soaked gauze (passive decompression)
Surgical revision / re-exploration
Hyperbaric oxygen therapy (HBO)
Negative pressure wound therapy (NPWT)
Observation and expectant management
Patient may refuse treatment at any time

Efectos secundarios comunes (esperados)

Efecto secundario	Frecuencia	Duración
Post-detachment bleeding/oozing	100%	4 to 24 hours (normal)
Mild sting/pinch at attachment	~100%	30 seconds to 2 minutes
Itching at bite site	37–75%	1–14 days; may be delayed
Local hematoma / ecchymosis	Common	5–14 days
Y-shaped bite scar	100%	Permanent; 2–3 mm; fades over months
Regional lymphadenitis	6–13%	Days to weeks; self-limiting

Riesgos serios (divulgación obligatoria)

Riesgo	Tasa	Detalles
Aeromonas infection	7–20% (without prophylaxis)	Prophylactic antibiotics reduce risk to <5%. Infection drops tissue salvage from 88% to 37.4%
Transfusion requirement	49.75% (surgical series)	Cumulative blood loss in serial protocols. Type & screen required for surgical patients
Allergic reaction / anaphylaxis	Rare (<1%)	IgE sensitization to leech SGS proteins; may occur on re-exposure
Treatment failure	22%	78% overall salvage rate; failure increases with infection, delay, and arterial insufficiency

Selección y dosificación de sanguijuelas por indicación

Criterios de selección

Selección de tamaño

Small (3–5 cm): Delicate areas — digits, ears, eyelids, pediatric
Standard (6–10 cm): Most indications — flaps, joints, general use
Large (>10 cm): Heavy decompression — large flaps, extensive congestion

Evaluación de actividad

Vigorous swimming when agitated
Rapid contraction when touched
Active exploration with anterior sucker
Firm muscular body tone

Verificación de hambre

Flat, non-distended body (not recently fed)
Actively seeking warm objects/skin
Unfed for minimum 2–4 weeks (supplier standard)
Never use a leech that has previously fed on a patient

Protocolo de dosificación específico por indicación

Indicación	Dosis estándar	Rango	Frecuencia	Contexto
Digit replantation	1–2	1–3	Every 2–4 hours	FDA-cleared; small leeches; serial application days 1–5
Ear replantation	1–2	1–3	Every 2–4 hours	FDA-cleared; small leeches; delicate tissue handling
Free flap (head/neck)	2–4	1–6	Every 2–8 hours	FDA-cleared; standard leeches; assess tissue color between sessions
DIEP/TRAM breast flap	2–3	1–4	Every 4–8 hours	FDA-cleared; standard to large leeches; larger surface area
Knee osteoarthritis	4–6	4–8	Single treatment	Periarticular placement; RCT-supported (Michalsen 2003, n=51)
Thumb CMC-1 OA	2–3	2–3	Single treatment	Small leeches; periarticular (Michalsen 2008, n=32)
Lateral epicondylitis	2–4	2–4	Single treatment	Over lateral epicondyle (Backer 2011, n=52)
Chronic low back pain	4–7	4–7	Single treatment	Paravertebral bilateral placement (Michalsen 2018, n=44)

Las filas sombreadas = indicaciones microquirúrgicas autorizadas por FDA 510(k).

Estimación de pérdida sanguínea

Each leech removes approximately 15–65 mL total: 5–15 mL during active feeding + 10–50 mL post-detachment oozing (anticoagulant effect of injected hirudin). For a single session with 6 leeches, anticipate 90–390 mL total blood loss.

Serial microsurgical protocol: 3–6 leeches every 4 hours × 5 days = potential cumulative blood loss of 2–5 liters. This is why 49.75% of microsurgical patients require transfusion (Whitaker 2012). Hematocrit monitoring every 4–8 hours is mandatory.

Preparación del sitio y técnica de aplicación

Preparación del sitio (5 pasos)

Clean with warm water only — NO alcohol, betadine, chlorhexidine, or any antiseptic. Chemical residues prevent leech attachment and may be toxic to the leech.
Shave hair if present — Leeches cannot attach through hair; clip or shave a 5 cm radius around each intended site.
Mark application sites — Use a surgical skin marker to indicate exact placement points. Essential for documenting bite locations and ensuring symmetric placement.
Apply application window (optional) — An adhesive ring or barrier film around the target area prevents leech migration to unintended sites. Especially useful for facial or periorbital application.
Protect surrounding areas — Absorbent underpads beneath the treatment area. Barrier drapes to prevent leech escape. Warm the skin if ambient temperature is low (warm moist gauze for 2–3 minutes).

Método de aplicación estándar (5 pasos)

Don nitrile gloves; have forceps, gauze, and containment supplies within reach
Transfer selected leech(es) from storage jar to a small clean container using blunt forceps
Invert the small container directly over the prepared application site; leech drops onto skin
Leech attaches within 30 seconds to 5 minutes — confirmed by rhythmic body contractions (peristaltic feeding movements)
Cover feeding leech loosely with moist gauze (3–4 layers) to maintain humidity and prevent desiccation; do not compress

Método de guía con jeringa (colocación precisa)

Remove plunger from a 5–10 mL syringe. Place leech inside the barrel with anterior (head) end toward the open tip.
Press syringe tip firmly against skin at the exact target point. The confined space directs the leech to attach at the precise location.
Once attached (rhythmic contractions visible), gently slide syringe barrel away. Optionally, pulling the plunger creates mild negative pressure to encourage engorgement.

Ideal para: Dígitos, orejas, colgajos pequeños, áreas cerca de estructuras críticas (ojos, orificios), o cuando se requiere colocación precisa en milímetros.

Resolución de problemas de rechazo de adhesión

Warm the skin with a moist warm gauze compress for 2–3 minutes (increases blood flow to surface)
Prick the skin with a sterile 25G needle to produce a small blood droplet at the target site
Try a different leech — some individual leeches are more responsive than others
Ensure no chemical residues on skin (alcohol, soap, perfume, antiseptic)
Check room temperature (must be 22–25°C) and absence of strong odors

Signo ominoso

El rechazo persistente de múltiples sanguijuelas a adherirse a un sitio quirúrgico (colgajo o reimplante) a pesar de piel tibia y gota de sangre puede indicar tejido no viable con perfusión inadecuada. Este es un hallazgo diagnóstico que debe impulsar una reevaluación quirúrgica urgente.

NUNCA jalar a la fuerza una sanguijuela en alimentación

La remoción forzada de una sanguijuela adherida arriesga: (1) regurgitación del contenido intestinal incluyendo Aeromonas hydrophila directamente en la herida, (2) avulsión de partes mandibulares incrustadas en el tejido que requieren remoción quirúrgica, y (3) trauma tisular en el sitio de mordida. Use técnicas de estimulación (algodón empapado en alcohol cerca del ventosa anterior) o espere el desprendimiento natural.

Monitoreo intraoperatorio

Monitoreo quirúrgico / hospitalario (6 parámetros)

Parámetro	Frecuencia	Umbral / Acción
Vital signs (HR, BP, SpO2, Temp)	Every 30 min during active feeding	Tachycardia >100, SBP <90, SpO2 <92%: reassess and intervene
Tissue assessment	Every 30 min (color, turgor, cap refill, Doppler)	Worsening congestion despite therapy: increase leech frequency or number; persistent arterial insufficiency: surgical re-exploration
Hematocrit / Hemoglobin	Every 4–8 hours	Transfuse if Hgb <7 g/dL (or <8 in CAD patients). 49.75% will need transfusion
Leech feeding status	Continuous visual observation	Detachment before 20 min: tissue may lack adequate perfusion. Failure to engorge: try different leech or reassess tissue viability
Post-detachment bleeding	Every 1–2 hours for first 6 hours	Count saturated gauze pads; >10 pads in 4 hours = activate bleeding algorithm
Pain assessment (NRS 0–10)	Every 2 hours	Score >5: acetaminophen 1000 mg PO/IV. Avoid NSAIDs. Score >7: consider opioid rescue

Monitoreo ambulatorio / musculoesquelético (3 parámetros)

Parámetro	Temporización	Acción
Vital signs	Before and after procedure	Document baseline and post-procedure; hold discharge if SBP <100 or symptomatic orthostasis
Pain (NRS)	Before, during, and 30 min after	Report sustained >5/10 after procedure. Document pain trajectory for efficacy assessment
Bleeding status	At detachment and 30 min post	Ensure manageable oozing before discharge; patient must demonstrate dressing management

Duración de alimentación y desprendimiento

Duración

Typical feeding: 20–45 minutes
Large leeches / heavy congestion: 60–90 minutes
Engorgement: 5–10× original body weight when fully sated
Leech detaches spontaneously when sated — do not rush

Técnicas de desprendimiento (si se necesita terminación temprana)

Natural: Wait for spontaneous detachment (preferred)
Stimulation: Gently touch cotton swab moistened with 70% alcohol or vinegar near (not on) the anterior sucker
Salt/alcohol: Place a few grains of table salt or a drop of alcohol adjacent to the head end
NEVER: Pull, twist, burn, or apply substances directly onto the leech body

Protocolo de eliminación (6 pasos)

Immediately place detached leech into 70% ethyl alcohol — euthanasia within minutes
Transfer euthanized leech to red biohazard waste container
Seal container when full; label with date and contents
Dispose through regulated medical waste stream per OSHA 29 CFR 1910.1030
Never reuse a leech that has fed on a patient (blood-borne pathogen transmission risk)
Never flush or dispose in sinks, toilets, or regular trash

Cuidado postprocedimiento de heridas

Manejo inmediato de heridas (5 pasos)

Apply clean dry gauze (4×4) directly over each bite site — do NOT apply direct pressure (oozing is therapeutic for venous decompression)
Layer additional absorbent pads over the initial gauze — expect significant saturation over 4–10 hours
Secure with medical tape or light wrap — no compression bandaging (compression defeats the purpose of continued oozing)
When blood saturates dressing, ADD layers on top — do NOT remove the underlying dressing for 24 hours (removing disrupts early clot formation)
Place absorbent underpads beneath the treatment area to protect bedding/clothing — especially important for overnight

Instrucciones de cuidado de heridas para el paciente (6 puntos)

Expect oozing through bandages for 4 to 24 hours — this is normal and expected
Add fresh gauze on top of saturated dressings; do not remove the bottom layer for 24 hours
After 24 hours: gently remove dressing, clean with warm water and mild soap only
Apply a clean dry dressing; change daily for 3–5 days until wound is dry
Do not apply hydrogen peroxide, alcohol, betadine, or antibiotic ointment to bite wounds
Keep the treatment area elevated above heart level when possible to reduce bleeding

Cronología del sangrado

Patrón de sangrado normal

0–2 hours: Active oozing, gauze saturates rapidly
2–6 hours: Gradual slowing; oozing continues but rate decreases
6 to 24 hours: Gradual cessation of oozing; dressings less saturated
10–24 hours: Complete cessation; wound begins to crust

Sangrado preocupante (activar algoritmo)

Persistent brisk bleeding beyond 10 hours
Saturating >10 gauze pads (4×4) in 4 hours
Hemodynamic changes: tachycardia, hypotension, dizziness, syncope
Visible pulsatile bleeding (arterial — rare but emergent)
Patient reports feeling faint or lightheaded

Cronología del sangrado

Los protocolos microquirúrgicos seriados (3–6 sanguijuelas c/4h × 5 días) pueden producir 2–5 litros de pérdida sanguínea acumulada. El hematocrito debe verificarse cada 4–8 horas. Transfundir cuando Hgb <7 g/dL (o <8 en pacientes con enfermedad coronaria). El 49.75% de los pacientes en la revisión sistemática de Whitaker 2012 requirieron transfusión.

Profilaxis antibiótica

La profilaxis antibiótica debe iniciarse al menos 1 hora antes de aplicar la primera sanguijuela y continuar durante todo el curso de tratamiento más 24–48 horas después de la última aplicación de sanguijuela. Sin profilaxis, las tasas de infección por Aeromonas son del 7–20%; con profilaxis, las tasas bajan a <5% (0% en Nguyen 2012, n=39).

Regímenes de primera línea

Régimen	Fármaco	Dosis	Vía	Duración
Preferred (Herlin 2017)	Ciprofloxacin + TMP-SMX DS	500 mg BID + 160/800 mg BID	PO	Through treatment + 24–48h after last leech
Monotherapy option A	Ciprofloxacin alone	500 mg BID	PO	Through treatment + 24–48h
Monotherapy option B	TMP-SMX DS alone	160/800 mg BID	PO	Through treatment + 24–48h

Regímenes alternativos (basados en alergia)

Alergia / Contraindicación	Régimen alternativo	Dosis	Vía
Fluoroquinolone allergy	TMP-SMX DS alone	160/800 mg BID	PO
Sulfonamide allergy	Ciprofloxacin alone	500 mg BID	PO
Both FQ + sulfa allergy	Ceftriaxone	1 g daily	IV
Pediatric patients	TMP-SMX pediatric dosing	4 mg/kg TMP + 20 mg/kg SMX BID	PO

Alerta de resistencia

Se ha documentado resistencia a ciprofloxacino en hasta el 43% de aislamientos ambientales de Aeromonas (Giltner 2013). Los genes de resistencia a quinolonas mediada por plásmidos (PMQR) se han encontrado en el 42% de las especies de Aeromonas de agua dulce. Esta es la razón principal para la profilaxis con doble agente (cipro + TMP-SMX) en lugar de la monoterapia con ciprofloxacino.

Evitar: cefalosporinas de primera generación (resistencia intrínseca de Aeromonas vía betalactamasas cromosómicas). Amoxicilina/ampicilina (actividad pobre contra Aeromonas).

Protocolo de vigilancia por lotes (instituciones que usan >50 sanguijuelas/mes)

On receipt: Culture 1 leech per batch (sacrifice for gut swab) — aerobic culture specifically requesting Aeromonas identification and susceptibilities
Every 30 days: Culture 1 leech from each active storage container to monitor for resistance drift during storage
Record results in institutional antibiogram specific to leech-sourced Aeromonas — track cipro, TMP-SMX, ceftriaxone, meropenem, and gentamicin susceptibilities
Adjust empiric prophylaxis based on batch-specific resistance patterns — if cipro resistance >20% in batch, switch to TMP-SMX monotherapy or add second agent
Report MDR isolates to the leech supplier, infection control committee, and state public health department if resistance to ≥3 classes is identified

Manejo del dolor y prurito

Protocolo de manejo del dolor

First-line: Acetaminophen 500–1000 mg PO q6h (max 4g/day); effective for mild-moderate post-procedure pain
AVOID NSAIDs for 48 hours post-procedure: Ibuprofen, naproxen, and ketorolac inhibit platelet function and prolong the anticoagulant effect of injected hirudin, significantly increasing bleeding duration
AVOID aspirin for 7 days post-procedure: Irreversible COX-1 inhibition compounds leech-induced anticoagulation
Moderate-severe pain: Opioid rescue — oxycodone 5 mg PO q4-6h PRN or tramadol 50 mg PO q6h; short course only
Surgical patients: IV acetaminophen 1000 mg q6h; PCA if multi-day protocol with significant pain

Manejo del prurito

El prurito en el sitio de mordida ocurre en el 37–75% de los pacientes. Es una reacción local mediada por histamina a las proteínas salivales, NO una reacción alérgica en la mayoría de los casos. El inicio puede ser inmediato o diferido 2–7 días.

Oral antihistamine: Cetirizine 10 mg daily (non-sedating) or diphenhydramine 25–50 mg q6h PRN (sedating)
Topical steroid: Hydrocortisone 1% cream applied to bite sites after 24 hours only (do not apply to actively oozing wounds)
Cool compress: 10–15 minutes PRN for symptomatic relief
Do NOT scratch: Risk of secondary bacterial infection of bite wounds

Algoritmo de sangrado excesivo

Un enfoque escalonado de 5 pasos para la hemorragia postdesprendimiento. La mayoría del sangrado se resuelve con los pasos 1–2. La progresión al paso 5 es rara pero requiere recursos inmediatos.

Paso 1 — Evaluación

Characterize bleeding: brisk flow vs. slow ooze
Count saturated gauze pads per hour
Check vital signs: HR, BP, orthostatics if ambulatory
Check most recent hematocrit; order STAT if >4h old
Review medications (anticoagulants, antiplatelets, NSAIDs)
Normal: Oozing for 4 to 24 hours post-detachment is expected and does not require intervention

Paso 2 — Medidas conservadoras

Add additional gauze layers; apply firm direct pressure for 15–20 minutes (timed)
Elevate the treatment area above heart level
Review and hold any anticoagulants/antiplatelets if clinically safe
Apply ice pack wrapped in cloth adjacent to (not directly on) wound

Paso 3 — Agentes hemostáticos tópicos

Silver nitrate stick: Apply directly to the bite wound for chemical cauterization (5–10 seconds per wound)
Topical thrombin: Apply directly to oozing wound surface
Absorbable gelatin sponge (Gelfoam): Pack into the Y-shaped bite wound and apply gentle pressure

Paso 4 — Cierre con sutura

Figure-of-eight suture through the Y-shaped bite wound using 3-0 or 4-0 absorbable suture
This is definitive local hemostasis for refractory bite-site bleeding
Consider aminocaproic acid (antifibrinolytic) if diffuse oozing from multiple sites
Order STAT CBC, PT/INR, aPTT, fibrinogen
Establish IV access if not already present

Paso 5 — Inestabilidad hemodinámica (raro)

IV crystalloid: Normal saline 500–1000 mL bolus for volume resuscitation
Type & crossmatch: Order immediately if not already current
Transfuse: pRBC if Hgb <7 g/dL (or <8 in CAD). FFP if INR >1.5. Platelets if <50K and actively bleeding
Discontinue leech therapy until hemodynamically stable and coagulopathy corrected
Hematology consult for refractory coagulopathy or DIC workup
Surgical consult if arterial bleeding suspected or local measures fail

49.75% of microsurgical patients require transfusion during leech therapy courses (Whitaker 2012). This is an expected complication, not a failure of technique.

Algoritmo de infección por Aeromonas

Aeromonas hydrophila es el principal riesgo infeccioso, representando el 88% de todas las complicaciones infecciosas. Inicio: 24 horas a 10 días (hasta 26 días). La infección reduce el salvamento tisular del 88.3% al 37.4% (Whitaker 2012).

Paso 1 — Reconocimiento (7 signos clínicos)

Expanding erythema >2 cm beyond bite site borders (mark and track)
Purulent or seropurulent drainage from bite wounds
Increasing pain after 48 hours (pain should be decreasing by this point)
Fever >38.0°C / 100.4°F
Regional lymphadenopathy (palpable tender nodes in draining basin)
Tissue necrosis or color change at or near bite sites
Systemic signs: rigors, tachycardia, hypotension, elevated WBC/CRP

Paso 2 — Acciones inmediatas

Wound culture: Aerobic swab; specifically request Aeromonas identification and full susceptibilities
Blood cultures ×2: If systemic signs (fever, tachycardia, hypotension)
Labs: CBC with differential, CRP, BMP, lactate if sepsis concern
Clinical photography: Document wound appearance; mark erythema borders with skin marker and timestamp
Escalate prophylactic antibiotics to empiric treatment doses (see table below)

Paso 3 — Terapia antibiótica empírica (por severidad)

Severidad	Criterios	Régimen	Vía
Mild	Local signs only; no systemic symptoms; stable vitals	Ciprofloxacin 500 mg BID + TMP-SMX DS BID	PO
Moderate	Spreading cellulitis; low-grade fever; elevated WBC	Ceftriaxone 1g daily + Ciprofloxacin 400 mg q12h	IV
Severe / Sepsis	High fever; hemodynamic changes; tissue necrosis; bacteremia	Meropenem 1g q8h + Gentamicin 5 mg/kg daily	IV

Paso 4 — Ajuste dirigido por cultivo

Narrow antibiotics based on culture susceptibilities (typically available 48–72h)
If MDR (multi-drug resistant): escalate to carbapenems (meropenem, imipenem)
Monitor resistance patterns; update institutional antibiogram
ID (Infectious Disease) consultation for MDR isolates or treatment failure

Paso 5 — Intervención quirúrgica

Debridement: Required if tissue necrosis develops; may require serial debridement
Emergent flap revision: If infection threatens the primary surgical reconstruction
Critical statistic: Infection drops tissue salvage from 88.3% to 37.4% — early, aggressive treatment is essential
Plastic surgery / microsurgery consultation mandatory for infected flaps

Cronología: inicio típico de 24 horas a 10 días posterapia; presentaciones tardías de hasta 26 días han sido documentadas. Mantener alto índice de sospecha durante todo el período de seguimiento.

Protocolo de reacción alérgica

Protocolo escalonado de tres niveles basado en la severidad de la reacción. La mayoría de las reacciones son locales (prurito/eritema en el sitio de mordida) y no requieren discontinuación de la terapia.

Nivel 1 — Reacción local (más común)

Prurito localizado, eritema o urticaria confinada al sitio de mordida y su vecindad inmediata.

Acción	Detalles
Oral antihistamine	Cetirizine 10 mg PO or diphenhydramine 25–50 mg PO
Topical steroid	Hydrocortisone 1% cream after 24h (not on open wound)
Cold compress	15 minutes PRN; cloth barrier between ice and skin
Documentation	Record reaction type and treatment in chart
Future therapy	NOT a contraindication — premedicate with antihistamine for future sessions

Nivel 2 — Reacción generalizada

Urticaria difusa, angioedema distante del sitio de mordida, prurito generalizado, síntomas GI o síntomas respiratorios leves.

Acción	Detalles
Discontinue therapy	Remove any remaining leeches using alcohol stimulation; do not force-pull
Diphenhydramine	50 mg IM (faster onset than PO)
Methylprednisolone	125 mg IV push (prevents biphasic reaction)
Observation	Minimum 4 hours monitoring for progression or biphasic reaction
Future therapy	Relative contraindication — allergy/immunology referral before considering retreatment

Nivel 3 — Anafilaxia

Hipotensión, broncoespasmo, edema laríngeo, colapso cardiovascular, pérdida de conciencia.

Acción	Detalles
1. Epinephrine	0.3 mg IM (anterolateral thigh); repeat q5–15 min PRN
2. Emergency code	Call 911 / activate code team; position patient supine with legs elevated
3. IV access	2 large-bore IVs (16–18G); NS 1–2L rapid infusion
4. Oxygen	High-flow O2 via non-rebreather mask (15 L/min)
5. Antihistamines	Diphenhydramine 50 mg IV + famotidine 20 mg IV (H1 + H2 blockade)
6. Bronchospasm	Albuterol 2.5 mg nebulized; repeat q20 min PRN
7. Steroids	Methylprednisolone 125 mg IV (prevents biphasic)
8. Disposition	ICU admission for monitoring minimum 12–24 hours
Future therapy	ABSOLUTE CONTRAINDICATION to future leech therapy

Indicadores de consulta

Escenario	Consulta	Acción / Umbral
Hgb <7 g/dL (or <8 in CAD)	Blood bank / Transfusion medicine	Transfuse pRBC; type & crossmatch; reassess leech therapy frequency
Refractory bleeding (Step 4–5)	Hematology	Coagulopathy workup; DIC screen; reversal agents; aminocaproic acid
Suspected Aeromonas infection	Infectious Disease	Culture-directed therapy; MDR management; antibiogram review
Tissue necrosis or flap compromise	Plastic Surgery / Microsurgery	Surgical debridement; flap revision; vascular re-exploration
Anaphylaxis or severe allergic reaction	Allergy/Immunology + ICU	Acute management per Tier 3 protocol; future leech therapy CI evaluation
INR >3.0 or aPTT >2x normal	Hematology / Cardiology	Anticoagulation management; bridge therapy; reversal consideration
Persistent leech refusal (surgical)	Primary surgical team	Tissue viability assessment; Doppler evaluation; consider surgical re-exploration
Pediatric patient	Pediatrics	Weight-based dosing for antibiotics and analgesics; smaller leech selection; parental consent
Elderly patient (>65 years)	Geriatrics / Primary Care	Polypharmacy review (anticoagulants, antiplatelets); renal dose adjustment for antibiotics (CrCl-based); reduced blood volume tolerance; baseline CBC with lower transfusion threshold; fall risk assessment if ambulatory

Calendario de seguimiento

Momento	Evaluación	Acciones
24 hours	Wound status; bleeding cessation; vital signs	Remove initial dressing; clean wounds; photograph. CBC if surgical/inpatient. Confirm antibiotics ongoing
72 hours (3 days)	Wound healing; infection screening; anemia	Assess for erythema, drainage, warmth (Aeromonas onset peak). Repeat CBC if serial protocol. Photograph wounds
1 week	Wound healing trajectory; delayed infection	Clinical photograph for record. Assess for late infection signs. Evaluate pain/function improvement (MSK patients). Suture removal if placed
2 weeks	Final wound assessment; scarring	Wounds should be fully epithelialized. Assess Y-shaped scar formation. Document final wound status photograph
4 weeks	Scar maturation; late infection surveillance	Late Aeromonas infection can present up to 26 days post-therapy. Final scar assessment. Functional outcome evaluation for MSK patients. Case closure documentation

Documentación: Lista de verificación preprocedimiento

Completar antes de iniciar la aplicación de sanguijuelas. Todos los elementos deben ser verificados y documentados.

Detección del paciente

Indication for leech therapy documented

Bleeding disorder screening completed (hemophilia, vWD, thrombocytopenia, hepatic coagulopathy)

Hepatic/renal function assessed

Immune status evaluated (immunosuppressants, HIV, transplant)

Cardiovascular history / anticoagulation status reviewed

Diabetes screening (type, HbA1c, neuropathy)

Prior leech therapy history obtained (reactions, infections, sensitization)

Revisión de alergias

Fluoroquinolone (ciprofloxacin) allergy: YES / NO — type: ___________

Sulfonamide (TMP-SMX) allergy: YES / NO — type: ___________

Leech saliva / hirudin allergy: YES / NO

Latex allergy: YES / NO (use nitrile gloves regardless)

Laboratorio

CBC obtained — Hgb: ___ g/dL Plt: ___K Date: ___

PT/INR obtained — INR: ___ Date: ___

Type & Screen current (<72h) [surgical/inpatient only]

BMP obtained [multi-day protocols]

Blood cultures drawn if febrile (active sepsis = absolute CI)

Medicamentos y consentimiento

Anticoagulant/antiplatelet medications reviewed; holds coordinated if applicable

Prophylactic antibiotics ordered and administered BEFORE first leech

Written informed consent obtained and signed (see Consent section)

Patient verbalized understanding of Y-scar, bleeding, infection risk, transfusion possibility

Verificación de equipamiento

Room temperature 22–25°C confirmed

Leeches inspected (quality criteria met, <30 days since receipt)

Emergency supplies present and in-date

Vital signs monitor functional

Biohazard container available; 70% ethanol for euthanasia

Documentación: Nota SOAP del procedimiento

S — Subjetivo

Chief Complaint / Indication: [venous congestion of ___ flap / knee OA pain / etc.]

Pain Level (Pre-procedure): NRS ___/10

Patient Understanding: Consent reviewed; patient verbalizes understanding of procedure, risks, alternatives, and right to refuse.

Relevant HPI: [surgical date, flap type, current tissue status, symptom duration]

O — Objetivo

Vital Signs (Pre): BP ___/___ HR ___ SpO2 ___% Temp ___°C

Labs: Hgb ___ g/dL Plt ___K INR ___ aPTT ___

Site Assessment (Pre): [color, turgor, cap refill, Doppler, temperature, edema]

Leeches Applied: ___ leeches, size: ___ cm, to [anatomic location(s)]

Attachment Time: ___:___ to ___:___ (duration: ___ min each)

Feeding Behavior: [normal peristalsis / sluggish / refusal — if refusal, number tried]

Detachment: Spontaneous / Stimulated (method: ___)

Blood Loss Estimate: ___ mL (feeding + oozing)

Site Assessment (Post): [color improvement, bleeding status, tissue viability]

Vital Signs (Post): BP ___/___ HR ___ SpO2 ___%

Pain Level (Post): NRS ___/10

Photographs: Pre and post procedure images obtained: YES / NO

A — Evaluación

Diagnosis: [Venous congestion of ___ flap, status post leech therapy session #___ / Knee OA, treated with leech therapy]

Response: [Improvement in tissue color/turgor/cap refill / Pain reduction from ___/10 to ___/10]

Complications: [None / Excessive bleeding / Refusal to attach / Allergic reaction — describe]

P — Plan

Next Session: [___ leeches in ___ hours / Single session complete]

Antibiotics: Continue cipro ___ mg BID + TMP-SMX DS BID × ___ days post-last leech

Monitoring: [Hct q___h / Vital signs q___min / Wound check q___h]

Pain: Acetaminophen ___ mg q___h PRN. Avoid NSAIDs × 48h.

Wound Care: Dry gauze dressing; do not remove × 24h; add layers if saturated

Follow-up: [24h wound check / 72h infection screen / 1 week assessment]

Disposition: [Remain inpatient for serial therapy / Discharge with instructions]

Documentación: Conjunto de órdenes postprocedimiento

Categoría	Orden
Activity	Bed rest with affected area elevated above heart level. Bathroom privileges with assistance. No ambulation unassisted × 4h post-procedure (orthostatic risk).
Diet	Regular diet. Encourage oral hydration ≥2L/day to support volume status. NPO if surgical re-exploration anticipated.
Medications — Antibiotics	Continue ciprofloxacin 500 mg PO BID + TMP-SMX DS PO BID. Duration: through treatment course + 24–48h after last leech.
Medications — Pain	Acetaminophen 1000 mg PO/IV q6h scheduled (max 4g/day). PRN: oxycodone 5 mg PO q4-6h for pain >5/10. AVOID NSAIDs × 48h, aspirin × 7 days.
Medications — Itching	Cetirizine 10 mg PO daily PRN itching. Diphenhydramine 25–50 mg PO q6h PRN severe itching (warn: sedation). Hydrocortisone 1% cream to bite sites after 24h.
Monitoring — Vitals	q30min during active feeding; q2h × 6h post-detachment; q4h thereafter (inpatient). Pre/post only (outpatient).
Monitoring — Labs	CBC q4–8h (serial inpatient protocol). STAT CBC if bleeding concerns or hemodynamic changes.
Transfusion	Type & Screen current. Transfuse pRBC for Hgb <7 g/dL (or <8 if CAD). FFP if INR >1.5 with active bleeding. Platelets if <50K with active bleeding.
Wound Care	Dry gauze dressing over bite sites; do not remove × 24h. Add gauze layers over saturated dressing. Absorbent underpads under treatment area. No compression wraps.
Notification Triggers	Notify physician for: HR >100 or <50; SBP <90; SpO2 <92%; Temp >38°C; Hgb <7; bleeding saturating >10 pads/4h; rash/urticaria; signs of anaphylaxis; patient distress.
Discharge Criteria (Outpatient)	Vitals stable; bleeding manageable; patient demonstrates dressing management; written discharge instructions provided; antibiotic prescription in hand; follow-up scheduled within 72h.

Documentación: Instrucciones de alta del paciente

Proporcionar en forma escrita al alta. Usar lenguaje sencillo apropiado al nivel de alfabetización del paciente.

Sangrado — qué es normal

Your bite wounds will ooze blood for 4 to 10 hours after the leeches are removed. This is normal and expected.
The bleeding will gradually slow down and stop completely within 12–24 hours.
Add clean gauze pads on top of your bandage if it becomes soaked. Do NOT remove the bottom layer for 24 hours.
Place a towel or absorbent pad under the treated area to protect your bedding and clothing.

Antibióticos — muy importante

Take ALL prescribed antibiotics exactly as directed. Do not skip doses.
Continue antibiotics for the full course, even if you feel fine.
Antibiotics prevent a specific bacterial infection (Aeromonas) that lives in the leech.
Take with food if you experience nausea. If you develop a rash, hives, or difficulty breathing, stop the medication and call your doctor or go to the ER immediately.

Manejo del dolor

Take acetaminophen (Tylenol) for pain: 500–1000 mg every 6 hours as needed (max 4000 mg/day).
Do NOT take ibuprofen (Advil/Motrin), naproxen (Aleve), or aspirin for at least 48 hours — these increase bleeding.
If prescribed a stronger pain medication, use it only as directed.

Prurito

Itching at the bite sites is very common (happens in up to 75% of patients) and is NOT an allergic emergency.
Take cetirizine (Zyrtec) 10 mg daily or diphenhydramine (Benadryl) 25–50 mg every 6 hours.
After 24 hours, you may apply hydrocortisone 1% cream to the bite sites.
Do not scratch the bite sites — this can cause infection.

Citas de seguimiento

72 hours (3 days): Wound check and infection screening
1 week: Healing assessment and photographs
2 weeks: Final wound evaluation
Keep all scheduled appointments even if everything seems fine

Vaya a la sala de emergencias inmediatamente si:

Bleeding that will not stop after 10 hours of firm pressure
Soaking through more than 10 gauze pads in 4 hours
Feeling faint, dizzy, lightheaded, or having a racing heartbeat
Fever above 100.4°F (38°C)
Increasing redness, swelling, warmth, or pus at the bite sites (especially after 48 hours)
Red streaks spreading from the bite sites
Rash, hives, swelling of face/throat, or difficulty breathing

Sobre sus cicatrices

Each leech leaves a small Y-shaped mark approximately 2–3 mm in size. These marks are initially red but will fade over several months to become faint, pale scars. They are permanent but typically barely noticeable once fully healed. Avoid sun exposure to healing bite sites for 3–6 months to minimize scar darkening.

Resumen de la evidencia

La siguiente tabla resume los estudios clave que informan estos protocolos clínicos. La evidencia abarca revisiones sistemáticas, ensayos controlados aleatorizados, cohortes prospectivas y directrices de consenso experto.

Base de evidencia de protocolos clínicos — estudios clave
Estudio	Diseño	Población (n=)	Intervención	Resultado clave	Resultado
Whitaker et al. 2012	Systematic review	Plastic/reconstructive surgery patients across 67 publications (1966-2009) (n=277)	Leech therapy with variable prophylaxis (79% received antibiotics)	Infection rate, salvage rate, transfusion rate	78% overall salvage; 49.75% transfusion rate; infection drops salvage from 88.3% to 37.4% Landmark review. 14.4% infection rate. 21.8% overall complication rate. 54.29% used concomitant anticoagulation
Herlin et al. 2017	Systematic review + retrospective cohort	Free flap patients requiring leech therapy (n=49)	Ciprofloxacin + TMP-SMX dual prophylaxis	Infection rate and flap salvage	83.7% salvage; low infection rate with dual therapy Established cipro + TMP-SMX as "most relevant" prophylaxis regimen
Michalsen et al. 2003	Randomized controlled trial	Patients with symptomatic knee osteoarthritis (n=51)	Single session of 4 leeches applied periarticular	Pain (VAS), function (WOMAC), at 7 and 28 days	Significant pain reduction sustained at 28 days; NNT 2–3 at day 7 First RCT of leech therapy for OA; seminal study
Michalsen et al. 2008	Randomized controlled trial	Patients with thumb carpometacarpal (CMC-1) osteoarthritis (n=32)	2-3 leeches applied to CMC-1 joint, single session	Pain, function, and grip strength at 7 and 28 days	Significant improvement in pain and function vs. topical diclofenac
Michalsen et al. 2018	Randomized controlled trial	Patients with chronic low back pain (n=44)	4-7 leeches applied paravertebral, single session	Pain (VAS), disability (ODI), at 28 days	Clinically significant pain reduction vs. back-care education control
Backer et al. 2011	Randomized controlled trial	Patients with lateral epicondylitis (tennis elbow) (n=52)	2-4 leeches applied to lateral epicondyle, single session	Pain (VAS), grip strength, DASH score at 7 and 28 days	Significant pain reduction and functional improvement vs. topical diclofenac
Giltner et al. 2013	Case report + genomic analysis	Patient with ciprofloxacin-resistant Aeromonas infection post-leech therapy (n=1)	Culture-directed antibiotic therapy after cipro failure	Clinical course and resistance mechanism identification	Cipro resistance confirmed; PMQR genes identified; successful treatment with alternative agents Highlighted need for dual-agent prophylaxis and batch surveillance
Palm et al. 2022	Institutional protocol study	High-volume leech therapy center (>50 leeches/month) (n=NR)	Batch culture surveillance protocol for incoming leech shipments	Antibiotic resistance patterns and protocol compliance	Identified variable resistance patterns between batches; informed empiric prophylaxis selection Model for institutional surveillance programs
Mumcuoglu et al. 2014	Expert consensus + literature review	Practitioners of medicinal leech therapy across all indications (n=NR)	Detailed clinical recommendations for leech use	Standardized protocols for selection, application, monitoring, and disposal	Published definitive best-practice guidelines covering facility, technique, and safety Most-cited procedural reference for medicinal leech therapy
Lineaweaver et al. 1992	Multicenter case series	Replantation and flap surgery patients with Aeromonas infection (n=10)	Documentation of post-leech Aeromonas infections across centers	Infection timing, severity spectrum, and tissue outcomes	Onset 24h to >10 days; severity from minor wound to tissue loss/sepsis Established the mandate for routine antibiotic prophylaxis
Nguyen et al. 2012	Prospective case series	Patients receiving leech therapy with standardized prophylaxis protocol (n=39)	Universal prophylactic antibiotics per standardized protocol	Aeromonas infection rate	0% infection rate (0/39 patients) Demonstrated that standardized prophylaxis can eliminate Aeromonas infection
Sig et al. 2017	Meta-analysis	Patients with knee osteoarthritis across RCTs and comparative studies (n=237)	Leech therapy (4-8 leeches, single or repeated sessions)	Pooled pain reduction (VAS) and function (WOMAC)	Statistically significant pain reduction (SMD -1.05) and functional improvement Strongest pooled evidence for musculoskeletal leech therapy

Puntos clave

Esenciales clínicos

Antibiotics before first leech: Ciprofloxacin 500 mg BID + TMP-SMX DS BID is the standard of care. Without prophylaxis, Aeromonas infection rates are 7–20%.
Never force-pull: Forcible removal risks Aeromonas regurgitation into the wound, tooth avulsion, and tissue trauma.
Blood loss is cumulative: 15–65 mL per leech. Serial protocols may cause 2–5 liters cumulative loss. 49.75% of surgical patients need transfusion.
Consent is the highest legal risk: Document nature, benefits, common side effects (6), serious risks (4 with statistics), and alternatives (5).
No antiseptics on application site: Clean with warm water ONLY. Alcohol, betadine, and chlorhexidine prevent attachment.

Monitoreo y seguridad

Hematocrit q4–8h in serial surgical protocols. Transfuse at Hgb <7 (or <8 in CAD).
Cipro resistance up to 43%: Dual-agent prophylaxis is recommended. Batch surveillance for institutions using >50 leeches/month.
Aeromonas onset up to 26 days: Maintain infection surveillance through the 4-week follow-up visit.
Itching is not allergy: 37–75% incidence. Treat with antihistamines. True anaphylaxis is rare (<1%) but requires permanent contraindication.
Avoid NSAIDs × 48h, aspirin × 7 days: Both prolong the anticoagulant effect of injected hirudin and increase bleeding risk.

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.